Trial Profile
Retrospective and Prospective Study of Long-term Use of Romidepsin in Patients
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 03 Oct 2021
Price :
$35
*
At a glance
- Drugs Romidepsin (Primary)
- Indications Cutaneous T-cell lymphoma
- Focus Therapeutic Use
- 10 Mar 2016 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 31 Aug 2015 Planned End Date changed from 1 Jan 2016 to 1 Jul 2016, as reported by ClinicalTrials.gov.
- 31 Aug 2015 Planned primary completion date changed from 1 Jan 2016 to 1 Jul 2015, as reported by ClinicalTrials.gov.